Project Grant R44HL178006
Award Date 9/5/25
Completion Date 8/31/28
Dollars Obligated $1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Lexington, MA 02421, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,963 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to New Health Sciences, Inc. (Hemanext Inc.) to evaluate the hemostatic function of platelets stored under hypoxic conditions for whole blood (WB) transfusion. The project aims to develop an improved WB storage platform that maintains an oxygen-managed environment to provide higher quality red blood cells for oxygen delivery and shock reversal, while...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will provide $646,383 to Emory University to evaluate the impact of donor and recipient factors on the survival of transfused red blood cells (RBCs) in recipients with sickle cell disease. The research aims to examine mechanisms contributing to RBC clearance in both the recipient and the donor, including the impact of RBC...
- This $568,264 Project Grant (R41HL178144) was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to SAFI Biotherapeutics Inc., a pre-clinical blood cell therapy company based in Cambridge, MA. The goal of this Phase I STTR project is to develop a scalable bioprocess for manufacturing designer red blood cells (RBCs) derived from induced pluripotent stem cells (iPSCs). These designer RBCs will serve as reagents to...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease. The project aims to test a novel lentiviral vector technology for efficiently editing hematopoietic stem cells to knockout the BCL11A enhancer, a key genetic target for sickle cell treatment. Through in vitro assays, the Phase I effort will...
- This Project Grant award of $234,000.00 was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the University of Colorado-Denver to develop "hemostatic red blood cells" (T-RBCs) that can bind to collagen and fibrin to enhance clot formation and stability. The goal is to create a novel technology to address severe, non-compressible bleeding, which is a major cause of mortality worldwide, especially in low-resource settings. The...
- This $2,024,340 Project Grant was awarded on August 15, 2025 by the National Heart Lung and Blood Institute (NHLBI), part of the National Institutes of Health, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports a multi-year research effort at Boston Children's Hospital to optimize outcomes for hematopoietic stem cell transplantation (HCT), an essential treatment for high-risk non-malignant and malignant hematologic diseases. The research project...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), will support the development of a mathematical model to study the oxygen-dependent equilibrium solubility of sickle hemoglobin in single red blood cells. The $719,128 award has an ultimate completion date of May 31, 2029 and aims to address the unmet need for mechanistic models of...
- This Project Grant award, valued at $465,000.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports research to investigate the mechanisms by which chronic inflammation disrupts the hemostatic balance in sickle cell disease (SCD). Specifically, the project aims to understand how tumor necrosis factor-alpha (TNFa) induced inflammation blocks autophagy and mitophagy in platelets and...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research CFDA program (93.837), awarded a $483,852 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a platform technology for measuring the kinetics and equilibrium concentration of sickle hemoglobin polymerization in single red blood cells. This technology aims to support drug potency assessment and patient risk stratification for sickle...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded Covenant Therapeutics LLC a $249,965 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) on September 10, 2023. The purpose of this grant is to further develop a novel therapeutic approach involving small peptide erythropoietin (EPO) analogs as an alternative to recombinant human EPO for the treatment of anemias, particularly those secondary to renal disease and malignancy. The key objectives are to optimize the lead...